Yezan Munther Haddadin

CIK: 0001718004

Transaction Breakdown

Open Market Buys (P)2 (28.6%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (71.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OTLK

Outlook Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

OTLK
Outlook Therapeutics, Inc.
Jun 2, 2026
Purchase(P)
Direct
29K shares at avg. $0.83$24K
OTLK
Outlook Therapeutics, Inc.
May 26, 2026
Purchase(P)
Direct
34K shares at avg. $0.44$15K
OTLK
Outlook Therapeutics, Inc.
Oct 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
96K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
286.7K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 3, 2024
Award(A)
Stock Option (Right to Buy)
Direct
19.8K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
132.3K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
56.6K shares-

		Type	Shares	Price		Ownership
Jun 2, 2026	OTLK Outlook Therapeutics, Inc.	Purchase(P)	29,000	$0.83	$24,145	Direct
May 26, 2026	OTLK Outlook Therapeutics, Inc.	Purchase(P)	34,000	$0.44	$14,960	Direct
Oct 3, 2025	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	95,969	-	-	Direct
Oct 1, 2025	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	286,734	-	-	Direct
Oct 3, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,771	-	-	Direct
Oct 1, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	132,293	-	-	Direct
Oct 1, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	56,636	-	-	Direct

1-7 of 7 transactions

About Haddadin Yezan Munther

Haddadin Yezan Munther (SEC CIK 0001718004) files insider reports with the SEC as Director of Outlook Therapeutics, Inc. (OTLK).

Signal8 holds 4 ownership filings by Haddadin Yezan Munther, all Form 4s, filed between Oct 3, 2024 and Jun 3, 2026. Those filings report 7 transactions, from Oct 1, 2024 to Jun 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Haddadin Yezan Munther's filings is in ISELIN, NJ.

Recent filings by Haddadin Yezan Munther

Jun 2, 2026: Open-market purchase of OTLK shares (Form 4, code P).
May 26, 2026: Open-market purchase of OTLK shares (Form 4, code P).
Oct 3, 2025: Grant or award of OTLK derivative securities (Form 4, code A).
Oct 1, 2025: Grant or award of OTLK derivative securities (Form 4, code A).
Oct 3, 2024: Grant or award of OTLK derivative securities (Form 4, code A).

Other insiders filing for Outlook Therapeutics, Inc. (OTLK)

Lundquist Kevin Michael, Chief Financial Officer
Jahr Robert Charles, Chief Executive Officer
Sukhtian Ghiath M., Director
KENYON LAWRENCE A, Chief Financial Officer
Sukhtian Faisal Ghiath, Director
THURMAN RANDY H, Director

How to read Form 4 transaction codes